CanAg^® CA125 EIA

CA125 is a high molecular weight mucin-type glycoprotein, originally defined by the Oc125 monoclonal antibody (MAb) established by Bast et al.¹. Different epitopes, co-expressed with the Oc125 epitope on the CA125 antigen, have been used for the development of heterologous assays for determination of the CA125 antigen². The CA125 EIA is based on two mouse monoclonal antibodies, Ov197 and Ov185, directed against two independent epitopes of the protein core of the CA125 antigen^{3, 4}. Assays for CA125 are frequently used to monitor patients with gynecological malignancies such as epithelial ovarian cancer⁵.
 

References

1. Bast R., Feeney M., Lazarus H., Nadler L., Colvin R., Knapp R., (1981). Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68: 1331 - 1337.

2. O'Brien T, Raymond L, Bannon G, Ford D, Hardardottir H, Miller F, Quirk J (1991). New monoclonal antibodies identify the glycoprotein carrying the CA125 epitope. Am J Obstet Gynecol 165: 1857 - 1864.

3. Nilsson O, Jansson E-L, Dahlen U, Nilsson K, Nustad K, Högberg T, Lindholm L (1994). In: Current Tumor Diagnosis: Applications, Clinical Relevance, Research, Trends. Ed R. Klapdor. Zuckswerdt Verlag München, pp 401-405.

4. Nustad K. et al., (1996) Specificity and affinity of 26 monoclonal antibodies against the CA125 antigen: First report from the ISOBM TD-1 Workshop. Tumor Biol 17:196-219.

5. Bonfrer J., Duffy M., Radtke, M., Segurado O., Torre G., van Dalen A., Zwirner M. (1999) Tumor markers in gynecological cancers-EGTM recommendations. Anticancer Research 19:2785-2820.